Featured Research

from universities, journals, and other organizations

Progress toward treatment for dangerous allergies

Date:
October 9, 2013
Source:
University of Notre Dame
Summary:
New research shows that a group of scientists has made concrete progress toward the development of the first-ever inhibitory therapeutic for Type I hypersensitive allergic reactions.

Peanuts, a common allergen.
Credit: pilotl39 / Fotolia

New research published in the journal Nature Chemical Biology shows that a group of scientists, led by faculty at the University of Notre Dame, has made concrete progress toward the development of the first-ever inhibitory therapeutic for Type I hypersensitive allergic reactions.

"Our allergy inhibition project is innovative and significant because we brought a novel molecular design approach to selectively inhibit mast cell degranulation -- the key event in triggering a food allergic response -- which has the potential to improve the quality of life for affected patients," said Basar Bilgicer, assistant professor of chemical and biomolecular engineering at Notre Dame and an investigator in the University's Advanced Diagnostics & Therapeutics initiative.

Allergic reactions are caused when a person's immune system reacts to normally harmless substances in the environment. An allergic reaction can be the source of a simple itch or sneezing; however, Type I hypersensitive allergic reactions can go as far as a life-threatening anaphylactic shock. Mast cells, which are a type of white blood cell, function to protect the body from harmful pathogens such as parasites. In Type I hypersensitive allergic conditions, mast cells show a response to otherwise harmless substances (allergens) and result in severe, even potentially lethal, symptoms. The most common examples to Type I hypersensitivity are food allergies, such as to peanuts or shellfish, which affect 15 million Americans and approximately 8 percent of children.

Through the new research, Bilgicer and his group designed a special molecule, called a heterobivalent inhibitor (HBI), which when introduced into a person's bloodstream can, in essence, out-compete allergens like egg or peanut proteins in their race to attach to mast cell receptors.

"Unlike current treatments, such as epinephrine, which help a body endure through an allergic reaction, our HBIs, if introduced into the bloodstream, would actually stop further progression of the allergic reaction from taking place," said Bilgicer.

"We are figuring out the optimum binding sites on the mast cell receptors to attach to, in order to prevent allergens from interacting with them and to prevent the allergic reaction before it even starts in the first place."

The team has demonstrated the effectiveness of their inhibitor molecule on allergic reaction using animal models of allergy. Their next set of targets are a variety of allergens that affect humans -- including peanuts, penicillin and dust mites -- and they will design HBIs that would be successful inhibitors for each.


Story Source:

The above story is based on materials provided by University of Notre Dame. Note: Materials may be edited for content and length.


Journal Reference:

  1. Michael W Handlogten, Tanyel Kiziltepe, Ana P Serezani, Mark H Kaplan, Basar Bilgicer. Inhibition of weak-affinity epitope-IgE interactions prevents mast cell degranulation. Nature Chemical Biology, 2013; DOI: 10.1038/nchembio.1358

Cite This Page:

University of Notre Dame. "Progress toward treatment for dangerous allergies." ScienceDaily. ScienceDaily, 9 October 2013. <www.sciencedaily.com/releases/2013/10/131009125955.htm>.
University of Notre Dame. (2013, October 9). Progress toward treatment for dangerous allergies. ScienceDaily. Retrieved September 18, 2014 from www.sciencedaily.com/releases/2013/10/131009125955.htm
University of Notre Dame. "Progress toward treatment for dangerous allergies." ScienceDaily. www.sciencedaily.com/releases/2013/10/131009125955.htm (accessed September 18, 2014).

Share This



More Health & Medicine News

Thursday, September 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

What HealthKit Bug Means For Your iOS Fitness Apps

What HealthKit Bug Means For Your iOS Fitness Apps

Newsy (Sep. 18, 2014) Apple has delayed the launch of the HealthKit app platform, citing a bug. Video provided by Newsy
Powered by NewsLook.com
Residents Vaccinated as Haiti Fights Cholera Epidemic

Residents Vaccinated as Haiti Fights Cholera Epidemic

AFP (Sep. 18, 2014) Haitians receive the second dose of the vaccine against cholera as part of the UN's vaccination campaign. Duration: 00:34 Video provided by AFP
Powered by NewsLook.com
Artificial Sweetener Could Promote Diabetes

Artificial Sweetener Could Promote Diabetes

Newsy (Sep. 17, 2014) Doctors once thought artificial sweeteners lacked the health risks of sugar, but a new study says they can impact blood sugar levels the same way. Video provided by Newsy
Powered by NewsLook.com
Ebola Vaccine Trial Gets Underway at Oxford University

Ebola Vaccine Trial Gets Underway at Oxford University

AFP (Sep. 17, 2014) A healthy British volunteer is to become the first person to receive a new vaccine for the Ebola virus after US President Barack Obama called for action against the epidemic and warned it was "spiralling out of control." Duration: 01:02 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins